Cyclin-dependent kinases initial approaches to exploit a novel therapeutic target

Pharmacology and Therapeutics

Volumn 82, Issue 2-3, 1999, Pages 285-292

  Sausville, Edward A ^a   Zaharevitz, Daniel ^a   Gussio, Robert ^a   Meijer, Laurent ^b   Louarn Leost, Maryse ^b   Kunick, Conrad ^c   Schultz, Robert ^a   Lahusen, Tyler ^a   Headlee, Donna ^a   Stinson, Sherman ^a   Arbuck, Susan G ^d   Senderowicz, Adrian ^a  

^a Developmental Therapeutics Program   (United States)

^b CNRS   (France)

^c UNIVERSITY OF HAMBURG   (Germany)

^d Cancer Therapy Evaluation Program   (United States)

Author keywords

Benzodiazepine; COMPARE; Cyclin dependent kinase; Drug treatment of neoplasms; Flavopiridol; Phase I trial

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZODIAZEPINE DERIVATIVE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVONOID; FLAVOPIRIDOL; KENPAULLONE; NSC 651704; NSC 657589; UNCLASSIFIED DRUG;

BINDING SITE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; COMPETITIVE INHIBITION; COMPUTER ANALYSIS; CONFERENCE PAPER; DIARRHEA; DRUG DESIGN; DRUG SCREENING; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; NEOPLASM; PATTERN RECOGNITION; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMANS; NEOPLASMS;

EID: 0033063777     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00062-X     Document Type: Conference Paper

References (33)

1. Bible K.C., Kaufmann S.M. Flavopiridol. a cytotoxic flavone that induces cell death in non-cycling A549 lung carcinoma cells Cancer Res. 56:1996;4856-4861.
2. Bible K.C., Kaufmann S.M. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents. the importance of sequence of administration Cancer Res. 57:1997;3375-3380.
3. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., Worland P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) and CDK4 in human breast carcinoma cells. Cancer Res. 56:1996;2973-2978.
4. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol. 147:1995;545-560.
5. de Azevedo W.F., Mueller-Dieckmann H.-J., Schulze-Gahmen U., Worland P.J., Sausville E., Kim S.-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA. 93:1996;2735-2740.
6. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., Kim S.-H. Crystal structure of cyclin-dependent kinase 2. Nature. 363:1993;595-602.
7. Dreyling M.H., Bulinger L., Ott G., Stilgenbauer S., Muller-Hermelink H.K., Bentz M., Hiddemann W., Dohner H. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res. 57:1997;4608-4614.
8. Gray N.S., Wodicka L., Thunnissen A.M., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeCler S., Meijer L., Kim S.H., Lockhart D.J., Schultz P.G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
9. Harper J., Elledge S. CDK inhibitors in development and cancer. Curr. Opin. Genet. Dev. 6:1996;56-64.
10. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
11. Jager W., Zembsch M., Wolschann P., Pittenauer E., Senderowicz A.M., Sausville E.A., Sedlacek H.H., Graf J., Thalhammer T. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci. 62:1998;1861-1873.
12. Kaur G., Stetler-Stevenson M., Sebers S., Worland P., Sedlacek H., Myers C., Czech J., Naik R., Sausville E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. 84:1992;1736-1740.
13. Krek W., Nigg E.A. Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle. identification of major phosphorylation sites EMBO J. 10:1991;305-316.
14. Krek W., Xu G., Livingston D.M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 83:1995;1149-1158.
15. Lorca T., Labbe J.-C., Devalut A., Fesquest D., Capony J.-P., Cavadore J.C., LeBouffant F., Doree M. Dephosphorylation of cdc2 on threonine 161 is required for cdc2 kinase inactivation and normal anaphase. EMBO J. 11:1992;2381-2390.
16. Losiewicz M.D., Carlson B.A., Kauer G., Suasville E.A., Worland P.J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201:1994;589-595.
17. Meijer L., Kim S.H. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 283:1997;113-128.
18. Meijer L., Borgne A., Mulner O., Chong J.P.J., Blow J.J., Inagaki N., Inagaki M., Delcros J.-G., Moulinoux J.-P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536.
19. Monks A., Scudiero D.A., Johnson G.S., Paull K.D., Sausville E.A. The NCI anti-cancer drug screen. a smart screen to identify effectors of novel targets Anticancer Drug Des. 12:1997;533-541.
20. Morgan D.O. Cyclin dependent kinases. engines, clocks, and microprocessors Annu. Rev. Cell. Dev. Biol. 13:1997;261-291.
21. Morla A.O., Draetta G., Beach D., Wang J.Y.J. Reversible tyrosine phosphorylation of cdc2. dephosphorylation accompanies activation during entry into mitosis Cell. 58:1989;193-203.
22. Norbury C., Blow J., Nurse P. Regulatory phosphorylation of the p34 cdc2 protein kinase in vertebrates. EMBO J. 10:1991;3321-3329.
23. Parker B.G.K., Kaur G., Nieves-Neira W., Taimi M., Kohlhagen G., Shimizu T., Losiewicz M.D., Pommier Y., Sausville E.A., Senderowicz A.M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood. 91:1998;458-465.
24. Paull K.D., Hamel E., Malspeis L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. Foye W.O. Cancer Chemo-Therapeutic Agents. 1995;9-45 American Chemical Society, Washington, DC.
25. Pines J., Hunter T. Human cell division. the involvement of cyclins A and B1, and multiple cdc2s Cold Spring Harbor Symp. Quant. Biol. 56:1991;449-463.
26. Schwartz G.K., Farsi K., Maslak P., Kelsen D.P., Spriggs D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res. 3:1997;1467-1472.
27. Schwartz G.K., Werner J.L., Maslak P., Saltz L., O'Reilly E., Kelsen D.P., Inzeo D., Sugarman A., Tong W., Spriggs D. Flavopiridol enhances the biological effects of paclitaxel. a phase I trial in patients with advanced solid tumors Proc. Am. Soc. Clin. Oncol. 17:1998;725.
28. Sedlacek H.H., Czech J., Naik R., Kaur G., Worland P., Losiewicz M., Parker B., Carlson B., Smith A., Senderowicz A., Sausville E. Flavopiridol (L8608275, NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 9:1996;1143-1168.
29. Senderowicz A.M., Headlee D., Stinson S.F., Lush R.M., Kalil N., Villalba L., Hill K., Steinberg S.M., Figg W.D., Tompkins A., Arbuck S.G., Sausville E.A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 16:1998;2986-2999.
30. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
31. Thomas J., Cleary J., Tutsch K., Arzoomanian R., Alberti D., Simon K., Feierabend C., Morgan K., Wilding G. Phase I clinical and pharmacokinetic trial of flavopiridol. Proc. Am. Assoc. Cancer Res. 38:1997;222.
32. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem. Pharmacol. 46:1993;1831-1840.
33. Yee A., Wu L., Liu L., Kobayashi R., Xiong Y., Hall F.L. Biochemical characterization of the human cyclin-dependent protein kinase activating kinase. J. Biol. Chem. 271:1996;471-477.